Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 61 for:    Melanoma | Denmark

The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03073031
Recruitment Status : Unknown
Verified April 2018 by Laerke Kjaer Tolstrup, Odense University Hospital.
Recruitment status was:  Recruiting
First Posted : March 8, 2017
Last Update Posted : April 17, 2018
Sponsor:
Collaborators:
REHPA
Rigshospitalet, Denmark
Danish Cancer Society
Information provided by (Responsible Party):
Laerke Kjaer Tolstrup, Odense University Hospital

Brief Summary:
This study evaluates if melanoma patients who report their side effects to immunotherapy weekly by the use of ePRO-CTCAE will experience an overall reduction of grade 3 and 4 events with 50% compared to routine monitoring carried out every 3 weeks.

Condition or disease Intervention/treatment Phase
Adverse Effects Device: Tablet: Samsung Galaxy Tab A Not Applicable

Detailed Description:

Hypothesis:

- Melanoma patients who report their side effects to immunotherapy by the use of PRO-CTCAE (Common Terminology Criteria for Adverse Events) will experience an overall reduction of grade 3 and 4 events with 50% compared to routine monitoring.

Aim:

  • Primary endpoint: To examine if the electronic tool PRO-CTCAE used on a weekly basis by patients receiving immunotherapy to supplement standard AE monitoring, results in cutting the frequency of grade 3 or 4 adverse events during treatment by 50% compared to patients who get a standard AE monitoring schedule every 3 weeks.
  • Secondary endpoints: 1)To examine if the time patients experience grade 2 or higher toxicity, differs in the two groups 2)To examine if more symptoms are reported in the intervention group 3) To examine if there is a difference between the 2 group when it comes to number of extra out-patient visits, days in hospital, telephone consultations and days in prednisone therapy 4) To examine if PRO-CTCAE is implementable in daily practice (will be explored in study 2 and 3).

Method:

All patients who are about to receive immunotherapy for the treatment of malignant melanoma at the Department of Oncology, Odense University Hospital (OUH), will be asked to participate. Patients who meet eligibility criteria will be randomized in a 1:1 ratio to either the intervention arm (the use of PRO-CTCAE) or the control arm (standard AE monitoring schedule). Approximately 70 patients in each arm. Inclusion will take place between September 2016 and July 2018. Patients in the intervention arm will report their events weekly for the first 12 weeks of treatment. Clinical staff and patients in the intervention arm will receive instructions on how to use the Ambuflex system to complete the electronic PRO-CTCAE questionnaire (patients) and include the reports in daily practice (clinical staff). Assistance from clinical staff will be provided to patients when needed. Moreover, hospital staff will receive education and written instructions on how to handle the weekly feedback form the patients in the intervention arm.

Evaluation: Studies show that 16% of patients treated with Pembrolizumab/Nivolumab experience grade 3 or 4 side effects during treatment. When it comes to Ipilimumab, the number is 27% and when the drugs are combined the number is as high as 55 %. It is however not all adverse events which the patients can report themselves and when biochemical AEs are deducted, it is estimated that the numbers suitable for self-reporting are as follows: Pembrolizumab/Nivolumab 10%, Ipilimumab 20%, Combination therapy 40%.The primary endpoint of the randomized trial is to reduce the frequency of grade 3 or 4 side effects from 10% to 5% for pembrolizumab /Nivolumab, from 20% to 10 % for Ipilimumab and from 40% to 20% for the combination theory. Realistically, 140 patients can be included in the course of 2 year according to the Danish Melanoma Group. A level of significance of 0.2 is accepted reaching a power of 0.61 for Pembrolizumab/Nivolumab, 0.80 for Ipilimumab) and 0,96 for the combination therapy. These numbers are acceptable due to the fact that this is a pilot study; PRO-CTCAE has not been used in connection with immunotherapy prior to this study and only in a few projects with other patients in Denmark. Moreover, it is prioritized that the Department of Oncology, OUH is the only site, so that the applicant can make sure that all relevant patients are recruited and that clinicians are constantly reminded of the project. Also, the applicant will be able to teach both patients and clinicians on how to use the tool. All in all, the collection of data will be easier and of a higher quality when the study is only being conducted in one site.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Use of PRO-CTCAE by Patients Receiving Immunotherapy for the Treatment of Malignant Melanoma
Actual Study Start Date : January 10, 2017
Estimated Primary Completion Date : May 2019
Estimated Study Completion Date : August 2019

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Active Comparator: Intervention
Patients report their adverse events on a tablet once a week (intervention) as a supplement to having them monitored every 3 weeks by a physician
Device: Tablet: Samsung Galaxy Tab A
No Intervention: Control
Patients have their side effects monitored by a physician every 3 weeks (control)



Primary Outcome Measures :
  1. The number of patients who experience drug-related grade 3 or 4 adverse events assessed by CTCAE 4.0 will be reduced by 50% in the intervention arm compared to patients in the control arm [ Time Frame: The first 6 months of treatment with immunotherapy ]

Secondary Outcome Measures :
  1. The time patients experience grade 2 or higher toxicity assessed by CTCAE, differs in the intervention arm and the control arm respectively [ Time Frame: The first 6 months of treatment with immunotherapy ]
  2. The number of drug-related adverse events assessed by CTCAE 4.0 reported in the intervention will be higher compared to the adverse events reported in the control arm [ Time Frame: The first 6 months of treatment with immunotherapy ]
  3. The number of contacts to the hospital will be higher in the intervention arm compared to patients in the control arm [ Time Frame: The first 6 months of treatment with immunotherapy ]
  4. The number of hospitalizations are fewer in the intervention arm compared to the control arm. [ Time Frame: The first 6 months of treatment with immunotherapy ]
  5. Patients in the intervention arm receive a lower accumulated prednisone dose compared to patients in the control arm [ Time Frame: The first 6 months of treatment with immunotherapy ]
  6. Patients in the intervention arm have a longer progression free survival compared to patients in the control arm [ Time Frame: Estimation of median PFS and progression free survival rate at 6, 12 and 24 months ]
    PFS is estimated using Kaplan Meier method and differences estimated using logrank test

  7. Patients in the intervention arm have a longer overall survival compared to patients in the control arm [ Time Frame: Estimation of median OS and overall survival rate at 6, 12 and 24 months ]
    OS is estimated using Kaplan Meier method and differences estimated using logrank test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women ≥18 years of age
  • who read and understand Danish,
  • who have been diagnosed with malignant melanoma,
  • who are about to be treated with immunotherapy for their disease (1st and 2nd line, mono-therapy and combination therapy).
  • Moreover, patients must have signed and dated a written informed consent form in accordance with regulatory and institutional guidelines and 6) be willing and able to comply with the completion of PRO-CTCAE and other required questionnaires.

Exclusion Criteria:

- None


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03073031


Contacts
Layout table for location contacts
Contact: Laerke K. Tolstrup, PhD student + 45 40295129 laerke.tolstrup@rsyd.sk
Contact: Lars Bastholt, MD lars.bastholt@rsyd.dk

Locations
Layout table for location information
Denmark
Odense University Hospital Recruiting
Odense, Denmark, 5000
Contact: Laerke K. Tolstrup, PhD-student    + 45 40295129    laerke.tolstrup@rsyd.dk   
Contact: Lars Bastholt, MD         
Sponsors and Collaborators
Odense University Hospital
REHPA
Rigshospitalet, Denmark
Danish Cancer Society
Investigators
Layout table for investigator information
Principal Investigator: Laerke K. Tolstrup, MD Odense University Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Laerke Kjaer Tolstrup, Principal investigator, Odense University Hospital
ClinicalTrials.gov Identifier: NCT03073031    
Other Study ID Numbers: SDUSF-2016-90/R1 - (548)
First Posted: March 8, 2017    Key Record Dates
Last Update Posted: April 17, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas